NASDAQ : CGEM
Cullinan Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 15.03 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 967.25M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 967.25M |
| Enterprise Value | 634.78M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 64.35M |
| Shares Outstanding | 64.35M |
| Shares Change (YoY) | +2.26% |
| Shares Change (QoQ) | +1.70% |
| Owned by Insiders (%) | 1.22% |
| Owned by Institutions (%) | 88.17% |
| Float | 48.09M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 33.21 |
| PB Ratio | 3.01 |
| P/TBV Ratio | 3.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.42 |
| Quick Ratio | 8.29 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -50.30% |
| Return on Assets (ROA) | -31.36% |
| Return on Invested Capital (ROIC) | -212.89% |
| Return on Capital Employed (ROCE) | -68.64% |
| Weighted Average Cost of Capital (WACC) | 4.02% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.91M |
| Employee Count | 109 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.04 |
| 52-Week Price Change | +95.45% |
| 50-Day Moving Average | 17.91 |
| 200-Day Moving Average | 15.81 |
| Relative Strength Index (RSI) | 45.32 |
| Average Volume (20 Days) | 753,551 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.64M |
| Short Previous Month | 7.63M |
| Short % of Shares Out | 11.87% |
| Short % of Float | 15.89% |
| Short Ratio (days to cover) | 6.17 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -221.81M |
| Pretax Income | -204.69M |
| Net Income | -208.34M |
| EBITDA | -221.49M |
| EBIT | -221.81M |
| Earnings Per Share (EPS) | -$3.47 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 334.54M |
| Total Debt | 2.07M |
| Net Cash | 332.47M |
| Net Cash Per Share | $5.17 |
| Equity (Book Value) | 321.75M |
| Book Value Per Share | 5.00 |
| Working Capital | 301.35M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -159.25M |
| Capital Expenditures | -49,000 |
| Depreciation & Amortization | 316,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -159.30M |
| FCF Per Share | -$2.48 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.26% |
| Shareholder Yield | -2.26% |
| Earnings Yield | -23.08% |
| FCF Yield | -16.47% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $34.60 |
| Price Target Difference | 130.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |